menu
    • menu
    [{"orgOrder":0,"company":"Sinntaxis","sponsor":"Addex Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2025","type":"Agreement","leadProduct":"Dipraglurant","moa":"mGlu5 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Sinntaxis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sinntaxis \/ Addex Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Sinntaxis \/ Addex Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by Sinntaxis

    Menu

    Sinntaxis

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Sinntaxis

                            Sweden arrow
                            ISPE Europe
                            Not Confirmed

                            Sinntaxis

                            Sweden arrow
                            ISPE Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dipraglurant

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Addex Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Addex Signs Option Deal with Sinntaxis for mGlu5 Use in Brain Injury Recovery

                            Details : Under the agreement, Sinntaxis and Addex will jointly advance the development of ADX48621 (dipraglurant), a phase II ready mGlu5 NAMr, as a potential treatment for patients with brain injuries.

                            Product Name : ADX48621

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            April 30, 2025

                            Lead Product(s) : Dipraglurant

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Addex Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth